A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Annual Price Revisions Should Continue in 2025 and Beyond: MOF Budget Examiner
May 15, 2024
-
BUSINESS As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
-
BUSINESS Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
-
ACADEMIA Researchers Crafting Japan’s 1st Guidelines for ALS Trials, Eye FY2026 Completion
May 14, 2024
-
BUSINESS Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
-
BUSINESS Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
May 10, 2024
-
BUSINESS Lilly Japan Nets 10% Sales Rise in 2023, Eyes No. 1 Growth for Protected Medicines
May 9, 2024
-
BUSINESS Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
-
ACADEMIA Japan to Forge National Registry for Leqembi, Test Genes to Predict Side Effects
May 8, 2024
-
REGULATORY New LDP Project Team Boots Up for Healthcare Transformation
May 8, 2024
-
BUSINESS Jevtana Supply Crunch amid Demand Spike Already Affecting Patients in Japan
May 7, 2024
-
BUSINESS Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
May 2, 2024
-
BUSINESS Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
-
BUSINESS Celltrion Japan Unveils New List of 5 Biosimilars in Development; Actemra and Pralia and More
May 1, 2024
-
REGULATORY Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
-
BUSINESS Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review
April 26, 2024
-
REGULATORY Japan Plans More Prompt Drug Approvals from 2025, Within 3 Weeks of Panel Nod
April 25, 2024
-
BUSINESS Rakuten Medical Ratcheting Up Overseas Expansion Drive for Akalux: Japan Chief
April 25, 2024
-
BUSINESS Bayer Poised to Navigate Patent Cliff with Blockbuster Hopefuls for Stroke, Kidney Disease
April 24, 2024
-
REGULATORY Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule
April 23, 2024
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…